BrP-LPA acts as both an Autotaxin inhibitor (94% inhibition at 10 uM) and pan LPA receptor antagonist (LPA1: 1.5 uM, LPA2: 1.4 uM, LPA3: 1.2 uM, LPA4: 0.27 uM). BrP-LPA inhibits the invasiveness of NIH3T3 ras ATX cells by 40% and decreases chemotaxis by 23%.. BrP-LPA reduces the size of breast (MDA-MB-231), colon (HCT-116) and melanoma (B16F10) tumors in mouse models. PPARg is not activated by BrP-LPA |
